NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a ...
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study ...
Nasus Pharma Ltd. NSRX shares are tumbling on Monday. The company announced topline results from its Phase 2 study of NS002, ...
Nasus Pharma Ltd. NSRX shares are down on Wednesday following the company's continuous weakness after the announcement of ...
Nasus Pharma (NYSE:NSRX) released top-line Phase 2 data for its investigational intranasal powder, NS002, that does more than just offer a needle-free alternative. The data suggests that Nasus has ...
Detailed price information for Serina Therapeutics Inc (SER-A) from The Globe and Mail including charting and trades.
TEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal ...
Not long ago, the notion that patients might swap the EpiPen experience for a needle-free alternative still felt speculative. It doesn’t anymore. ARS Pharmaceuticals’ Neffy - a nasal spray approved in ...
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based ...
TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative ...
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results